Jump to:
Comments: 1
Tritace (ramipril) is now licensed for the treatment of incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, or manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥3g/day.
Further information: Sanofi-aventis
You must log in to comment on articles.
New users can register here free for full access.
Educational resource for the learning and teaching of the
GP curriculum
Cumulative list of products discontinued from the UK market
in 2010
Healthcare Republic resource centre for diagnosing and managing psoriasis
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
A Haymarket Publication © 1957 – 2010
This information adds value to my brand.
Report this post